38 results
SC 13E3/A
EX-99
STSA
Satsuma Pharmaceuticals Inc
8 Jun 23
Going private transaction (amended)
9:16am
in effect.
“FDA” means the U.S. Food and Drug Administration.
“Financial Expert” means an independent certified public accounting firm of nationally … to do so, Parent and the Acting Holders (on behalf of the CVR Holders) shall jointly engage the Financial Expert, whose appointment shall be final
SC 14D9/A
STSA
Satsuma Pharmaceuticals Inc
30 May 23
Tender offer solicitation (amended)
9:42pm
be consummated, an injunction directing the Company Board to comply with the Act, and an award of attorney’s and expert fees and expenses. Purchaser and Parent … with the Act, and an award of attorney’s and expert fees and expenses. Purchaser and Parent are not named as parties to the lawsuits. The above
SC 14D9
STSA
Satsuma Pharmaceuticals Inc
5 May 23
Tender offer solicitation
8:17am
with no further clinical trials (based on interactions with the FDA and input from its expert regulatory consultants), (ii) the commercial potential
8-K
EX-10.1
xto wvsrw5bnpfgyf
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
SC TO-C
EX-99.2
i2y r7hcxv
17 Apr 23
Information about tender offer
6:08am
8-K
EX-99.1
rvhbtbd irxhxo5ej
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.2
debknfnnzt tqajtk
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.1
0hj8mt1a p2rk4gbkm0c
30 Nov 22
Other Events
4:00pm
8-K
EX-99.1
61tt2ll84yyr37b
1 Mar 21
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
12:00am